Skip to main
ENLV

ENLV Stock Forecast & Price Target

ENLV Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Enlivex Therapeutics is well-positioned financially to advance its immunotherapy candidate, Allocetra, due to the existence of an at-the-market (ATM) facility that enables the company to capitalize on elevated trading volume, thereby enhancing liquidity and sustaining operational momentum. The company's Phase IIa trial results indicate statistically significant and clinically meaningful improvements in pain reduction and functional outcomes, especially among patients aged 60 and over, which represents a substantial segment of the osteoarthritis market. Furthermore, the recent patent application concerning Allocetra in osteoarthritis strengthens its intellectual property position, further supporting the rationale for continued investment and development of the promising drug pipeline.

Bears say

Enlivex Therapeutics's stock faces a negative outlook primarily due to the uncertain implications of its strategic pivot, which raises concerns about future performance and market perception. The disparity between the company's clinical progress and its market recognition has led management to adopt unconventional capital access strategies, reflecting potential weaknesses in investor engagement. Additionally, while there are expectations that upcoming milestones could de-risk specific programs, the overall lack of clarity surrounding these developments adds to the apprehensions regarding the company's financial stability and growth potential.

ENLV has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Enlivex Therapeutics Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Enlivex Therapeutics Ltd (ENLV) Forecast

Analysts have given ENLV a Strong Buy based on their latest research and market trends.

According to 2 analysts, ENLV has a Strong Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Enlivex Therapeutics Ltd (ENLV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.